Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 24:8:644189.
doi: 10.3389/fcvm.2021.644189. eCollection 2021.

Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective

Jing Cui  1   2 , Yanfei Liu  3 , Yiwen Li  1   2   4 , Fengqin Xu  2   4 , Yue Liu  1   2   4
Affiliations
Review

Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective

Jing Cui et al. Front Cardiovasc Med. .

Abstract

Type 2 diabetes mellitus (T2DM) and its complications are seriously affecting public health worldwide. Myocardial infarction (MI) is the primary cause of death in patients with T2DM. T2DM patients without a history of coronary artery disease (CAD) have the same risk of major coronary events as those with CAD; T2DM patients with a history of MI have >40% risk of recurrence of MI. Thus, CAD in patients with T2DM needs to be treated actively to reduce the risk of MI. The cardiology community focused on the role of T2DM in the development of CAD and on the related issues of T2DM and MI with respect to comorbidities, prognosis, drug therapy, and heredity. In this mini review, the latest progress of clinical evidence-based research between T2DM and MI in recent years was reviewed, and the possible research directions in this field were considered and prospected.

Keywords: drug; evidence-based medicine; myocardial infarction; sodium-glucose cotransporter-2 inhibitor; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Cardiorenal benefit of oral hypoglycemic agents in therapeutic focus of type 2 diabetes mellitus (T2DM).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: current situation and perspectives. Eur J Prev Cardiol. (2019) 26:7–14. 10.1177/2047487319881021 - DOI - PubMed
    1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. . IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for (2045). Diabetes Res Clin Pract. (2018) 138:271–81. 10.1016/j.diabres.2018.02.023 - DOI - PubMed
    1. Yang JJ, Yu D, Wen W, Saito E, Rahman S, Shu XO, et al. . Association of diabetes with all-cause and cause-specific mortality in asia: a pooled analysis of more than 1 million participants. JAMA Netw Open. (2019) 2:e192696. 10.1001/jamanetworkopen.2019.2696 - DOI - PMC - PubMed
    1. Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, et al. . Prevalence and ethnic pattern of diabetes and prediabetes in China in (2013). JAMA. (2017) 317:2515–23. 10.1001/jama.2017.7596 - DOI - PMC - PubMed
    1. Avogaro A, Bonora E, Consoli A, Del Prato S, Genovese S, Giorgino F. Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. Diab Vasc Dis Res. (2019) 16:399–414. 10.1177/1479164119845612 - DOI - PubMed

LinkOut - more resources